ARENTFOX SCHIFF LLP for CSL BEHRING
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Orphan drug exclusion within the pharmaceutical tax in the Patient Protection and Affordable Care Act H.R. 2672 (Preserving Access to Orphan Drugs Act of 2011), all provisions
Foreign entity interest: CSL Limited, identified in the LD-1, is interested in U.S. tax policies that may affect the business of its subsidiary CSL Behring.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| LAURA EUGSTER DOYLE | — |
Budget/Appropriations BUD
FY '12 Centers for Disease Control funding opportunities regarding Primary Immunodeficiency diseases research and programs FY '12 (S. 1599 and H.R. 3070 (Title II), and Consolidated Appropriations Act, 2012) Labor/HHS/Education Appropriations regarding Centers for Disease Control funding opportunities for Primary Immunodeficiency diseases research and programs
Foreign entity interest: CSL Limited, identified in the LD-1, is interested in the existence of funding for programs that may affect the business of its subsidiary CSL Behring.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| LAURA EUGSTER DOYLE | — |
| DAN RENBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.